Your browser doesn't support javascript.
loading
Tratamiento farmacológico actual de la hipertensión arterial pulmonar / Pharmacological treatment of pulmonary arterial hypertension
Pulido Zamudio, Tomás.
Affiliation
  • Pulido Zamudio, Tomás; Instituto Nacional de Cardiología Ignacio Chávez. Departamento de Cardioneumología. MX
Arch. cardiol. Méx ; Arch. cardiol. Méx;77(supl.4): S4-198-S4-201, oct.-dic. 2007. ilus
Article in Es | LILACS | ID: lil-568692
Responsible library: BR1.1
ABSTRACT
Until recent years, pulmonary arterial hypertension was considered as an untreatable disease. However, with the better knowledge in its pathobiology, new drugs have been developed. These new drugs can be divided in three main groups 1. Prostacyclin analogs (Epoprostenol, iloprost, treprostinil); 2. Endothelin antagonists (Bosentan, sitaxsentan); and 3. Phosphodiesterase-5 inhibitors (Sildenafil). Numerous studies have evaluated the safety and efficacy of these drugs, showing significant improvement in exercise capacity, quality of life and time to worsening. Some of them have even showed a better survival when compared with conventional treatment. Despite these advances, pulmonary arterial hypertension remains an incurable disease, so the focus of new studies is the combination of two or more drugs with a different mechanism of action.
Subject(s)
Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Hypertension, Pulmonary Aspects: Patient_preference Limits: Humans Language: Es Journal: Arch. cardiol. Méx Journal subject: CARDIOLOGIA Year: 2007 Document type: Article Affiliation country: Mexico Country of publication: Mexico
Full text: 1 Collection: 01-internacional Database: LILACS Main subject: Hypertension, Pulmonary Aspects: Patient_preference Limits: Humans Language: Es Journal: Arch. cardiol. Méx Journal subject: CARDIOLOGIA Year: 2007 Document type: Article Affiliation country: Mexico Country of publication: Mexico